High-dose-rate brachytherapy as monotherapy for prostate cancer

Demanes, D. Jeffrey; Ghilezan, Michel

doi:10.1016/j.brachy.2014.03.002

Cited by 92 publications

(74 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1995, the first trial of HDR-BT as a monotherapy was introduced at Osaka University, Japan (10). Since then, >80 articles and abstracts on HDR monotherapy have been published, with a variety of doses and fractionations (7).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer

Ashida

Yamasaki

Takagi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the feasibility and preliminary outcomes of high-dose-rate (HDR)-brachytherapy as a monotherapy in two fractions within 1 day for localized prostate cancer, including high-/very high-risk cases. Among the 68 patients treated with HDR monotherapy between July 2011 and December 2014, 65 had a minimal follow-up of 12 months without adjuvant androgen deprivation therapy and were enrolled in the present study [42/65 (64.6%) exhibited high-/very high-risk diseases]. HDR monotherapy was performed in two fractions with a minimal interval of 6 h and the prescribed dose was 13.5 Gy (x2). Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events (version 4;

show abstract

Section: Discussionmentioning

confidence: 99%

“…An increasing number of articles on HDR monotherapy have been reported (7). However, little is reported about high or very high-risk cases treated with 1-day HDR monotherapy.…”

Section: Introductionmentioning

confidence: 99%

Feasibility and early outcome of high-dose-rate Ir-192 brachytherapy as monotherapy in two fractions within 1 day for high-/very high-risk prostate cancer

Ashida

Yamasaki

Takagi

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…High-dose-rate brachytherapy (HDR-BT) for prostate cancer is an effective prostate cancer therapy that can be delivered as a monotherapy (Demanes et al 2014) 1–6 or a boost to external beam radiotherapy. 7–16 While achieving tumor control is paramount, prostate cancer patients may live with the side effects of their treatment for decades, and anticipated side effects play a strong role in treatment decisions.…”

Section: Introductionmentioning

confidence: 99%

Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer

Dadkhah

Hopfensperger

Kim

et al. 2017

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose To present a novel multisource rotating shield brachytherapy (RSBT) apparatus for the simultaneous precise angular and linear positioning of partially-shielded 153Gd brachytherapy sources in interstitial needles for the treatment of locally-advanced prostate cancer. It is designed to lower the dose to nearby healthy tissues, the urethra in particular, relative to conventional high-dose-rate brachytherapy (HDR-BT) techniques. Methods and Materials Following needle implantation through the patient template, an angular drive mechanism is docked to the patient template. Each needle is coupled to a multisource afterloader catheter by a connector passing through a shaft. The shafts are rotated about their axes by translating a moving template between two stationary templates. Shafts’ surfaces and moving template holes are helically threaded with the same pattern such that translation of the moving template causes simultaneous rotation of the shafts. The rotation of each shaft is mechanically transmitted to the catheter/source/shield combination, inside the needles, via several key/keyway pairs. The catheter angles are simultaneously incremented throughout treatment, and only a single 360° rotation of all catheters is needed for a full treatment. For each rotation angle, source depth in each needle is controlled by a multisource afterloader, which is proposed as an array of belt-driven linear actuators, each of which drives a wire that controls catheter depth in a needle. Results Treatment plans demonstrated RSBT with the proposed apparatus reduced urethral D0.1cc below that of conventional HDR-BT by 31% for urethral dose gradient volume within 3 mm of the urethra surface. Treatment time to deliver 20 Gy with the proposed multisource RSBT apparatus using nineteen 62.4 GBq 153Gd sources is 122 min. Conclusions The proposed RSBT delivery apparatus enables a mechanically feasible urethra-sparing treatment technique for prostate cancer in a clinically reasonable timeframe.

show abstract

“…The biochemical control rate in favourable risk PC patients has been shown to be good for different radiotherapy treatment options [1][2][3][7][8][9]. Therefore, toxicity rates and health-related quality of life (QoL) are important and relevant factors for patients to choose between the different treatment options.…”

mentioning

confidence: 99%

“…High-dose-rate brachytherapy (HDR-BT) is a safe and effective treatment option for prostate cancer (PC) [1][2][3]. There is accumulating evidence that PC cells have a higher sensitivity to fraction dose, which suggests a significant therapeutic benefit of hypofractionation [4,5].…”

mentioning

confidence: 99%